Apr. 27, 2015
On Apr 27, 2015, Resverlogix Corp. announced that it has entered into a framework agreement with Shenzhen Hepalink Pharmaceutical. The agreement includes an equity investment of over $40 million and a license of RVX-208 for China, Hong Kong, Taiwan and Macau.
Total sales-based milestones and royalty payments are estimated to be in excess of $400 million.